Hemophilia A results from a deficiency in factor Vlll (FVIII), a cofactor in the intrinsic pathway of blood coagulation. As an approach toward genetic therapy of this disease, we constructed a retroviral vector encoding human FVlll and a selectable and amplifiable genetic marker, human adenosine deaminase (Ada). A retrovirus packaging line was transfected with this vector and stable transformants were selected for Ada expression. Isolated transformants produced both FVlll activity in the conditioned medium and retrovirus capable of transferring the Ada selectable marker and FVlll expression to mouse 3T3 fibroblasts. Selection of EMOPHILIA A, or classical hemophilia, is a congeni-
EMOPHILIA A, or classical hemophilia, is a congeni-H tal X-chromosome-linked disease characterized by uncontrolled bleeding episodes. The disorder afflicts approximately 1 in 10,000 males and results from a deficiency in factor VI11 (FVIII). Treatment of hemophilia A requires infusion of FVIII preparations derived from human plasma. While this replacement therapy is effective in controlling many bleeding episodes, patients may suffer many complications, including infection by viruses prevalent in the blood donor population. Some of the problems associated with this therapy have been reduced by the use of virus-inactivation steps and monoclonal antibodies (MoAbs) during FVIII purification from plasma,' and recently by the use of recombinant FVIII.* However, the prophylactic treatment of hemophilia A is still limited by the cost and availability of FVIII, as well as by the difficulties associated with intravenous infusion. Newer forms of administration, such as constant release devices or eventually somatic cell gene therapy, would be advantageous in the treatment of this disease. With this aim, we engineered a retrovirus that is capable of transmitting FVIII expression to fibroblast cells.
The cloning of the FVIII gene has permitted the elucidation of the FVIII protein structure and the derivation of cell lines capable of expressing the recombinant p r~t e i n .~ The full-length cDNA contains an open reading frame of 2,351 amino acids!. ' The FVIII protein is processed into an amino-terminal heavy chain of approximately 200 Kd, and a carboxy-terminal light chain of approximately 80 Kd. FVIII is composed of repeated domains present in the order Al-A2-B-A3-Cl-C2. The heavy chain contains the highly glycosylated B domain, which has 19 of the 25 potential N-linked glycosylation sites present in FVIII. While liver is most likely the site of FVIII biosynthesis,6.' there are no known natural cell lines that express this clotting protein. Expression of FVIII activity in CHO cells containing amplified copies of the FVIII cDNA gene is reduced 2 to 3 orders of magnitude relative to the expression of other recombinant proteins. Inefficient expression of FVIII can be accounted for by low levels of messenger RNA (mRNA) and inefficient processing and secretion of the primary translation product. ' In addition, accumulation of FVIII activity in the conditioned medium requires von Willebrand factor to promote stable secretion from the cell. FVIII molecules, which contain deletions within the B-domain, retain in vitro and in vivo procoagulant activity.'." Although expression of B-domain-deleted FVIII is somewhat more efficient, it is still subject to the same factors that limit expression of the wild-type molecule. In this report we demonstrate the feasibility of retroviral transfer of functional FVIII.
MATERIALS AND METHODS
Cells and culture conditions. 3T3 cells were cultured in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine serum. Selection for adenosine deaminase (Ada) expression" was in the same medium supplemented with 4 pmol/L xyol-A (4-XA) (obtained from the Drug Synthesis and Chemistry Branch, Division of Cancer Treatment and Chemistry, National Cancer Institute, Bethesda, MD) and the indicated concentrations of 2'-deaxycoformycin (dCF) (Sigma, St Louis, MO). PA317 cells were obtained from Dusty Miller (Fred Hutchinson Cancer Research Center, Seattle, WA)." The derivation and growth of CHO cell line LA3-5, which expresses B-domain4eleted FVIII, was previously des~ribed.'~ The starting retroviral vector was pAFVXM. pAFVXM is virtually identical to pEVX,I5 except that it lacks the Moloney murine leukemia virus splice donor site, and has more unique cloning sites (Michael Kriegler, personal communication, April 1985). The BglII site within pAFVXM was converted to an XhoI site using synthetic linkers, yielding pAFVXM-Xho. The PvuII to HinFI fragment from pSV2Ada,16 containing the SV40 early promoter and human Ada cDNA, was ligated into the ClaI site of pAFVXM-Xho. Before ligation, the CIaI and HinFI ends were rendered blunt with the Klenow fragment of DNA polymerase I in the presence of deoxynucleotide triphosphates. The desired product (pAFVXM-SVAda) contains the SV2Ada transcription unit in the same orientation as the long terminal repeat (LTR) promoter. The XhoI to Sal1 fragment encoding the LA B-domain-deleted FVII19 was cloned into the XhoI site of pAFVXM-SVAda in the same orientation as Ada to yield pRetroLA-SVAda (Fig 1) . All plasmids were checked by restriction endonuclease digestion and agarose gel electrophoresis.
PA317 cells were transfected by protoplast fusion as previously described." Two days later cells were selected for Ada expression as described above and independent stable derivatives were termed LAR. Viral infections. LAR cells were plated at approximately 25% confluence in IO-cm tissue culture plates. The next day, the medium was replaced with 5 mL fresh medium. The conditioned medium was passed through a 0.45 pm filter 24 hours later and used as the viral stock. 3T3 cells were grown in IO-cm tissue culture plates and incubated with the viral stocks in complete medium supplemented with 8 pg/mL polybrene in a final volume of 3 mL. After 2 hours, 7 mL of medium was added. Cells were allowed to incubate an additional 48 hours, and then subcultured (1:lO) into Ada selective medium. Colonies were counted 12 to 14 days later.
Intracellular and secreted forms of FVllI were analyzed after labeling cells with ["SI-methionine as previously described.) Cell extracts and conditioned medium were immunoprecipitated with an MoAb (F8-1.5.6)) specific to the heavy chain of human FVIII. Immunoprecipitates were electrophoresed through an 8% polyacrylamide gel under reducing conditions and analyzed by fluorography. FVIII activity was quantitated in 24-hour conditioned medium from near-confluent cultures by measuring the FVIII-dependent generation of factor Xa from factor X (Kabi Coatest method).
Analysis of DNA and RNA. Total cellular RNA'* and high molecular weight cellular DNA'9 -were prepared as previously described from 3T3 cells, PA317 cells, and derivatives selected for Ada and FVllI expression. For Northern blot analysis:' IO &lane of RNA was electrophoresed through a 1% agarose/formaldehyde gel. DNA was digested with BamHl restriction endonuclease and electrophoresed through a 0.8% agarose gel (10 pgllane). RNA and
Transfection.
Analysis of FVIII expression.
DNA were transferred to nitrocellulose filters and hybridized to either FVIII or Ada cDNA fragments that were labeled by nicktranslation. Bacterial protoplasts containing pRetro LA-SVAda were prepared and fused to PA317 cells, a 3T3-derived cell line that provides in trans the necessary components to package retroviral genomes." Transfected cells were selected for expression of Ada by growth in xyol-A and 5 nmol/L or 10 nmol/L dCF.I2 Control-treated cells that did not receive bacterial protoplasts were killed on propagation in 5 nmol/L dCF. Individual clones, termed LAR (cl-c17, where each number represents a unique clone) were isolated and expanded.
RESULTS

Construction
All LAR clones produce FVIII activity in the conditioned medium as monitored by a chromogenic assay for factor Xa generation ( Table 1 ). The FVIII activity was inhibited by a human anti-FVIII neutralizing MoAb (F8.1.5.6). No FVIII activity was detected in conditioned medium obtained from the original PA317 packaging line. Because all clones that exhibit the dCF resistance phenotype also express FVIII activity, it is unlikely that the plasmid DNA has undergone rearrangement during integration.
Infection of 3T3 cells and amplification of virus titers. Several LAR clones were tested for the production of virus capable of transfering the Ada marker to 3T3 cells. Infected and mock-infected cells were selected for Ada expression by growth in xyol-A and dCF. The results ( Table 1 , top) show that several LAR clones produce viruses capable of transferring the drug-resistant phenotype to 3T3 cells. Individual clones or pools of infected 3T3 cells, termed 3A8 (the number after 3A8 indicates which LAR packaging line was used to generate retrovirus; c or p indicates a clone or pool of infected cells, respectively), were isolated and expanded for further analysis.
To increase virus titer in the LAR cell lines, we selected for increased Ada expression. The packaging line LARcl7, selected and grown initially in 5 nmol/L dCF, was sequentially selected in 100 nmol/L and 1,000 nmol/L dCF. A stringent selection occurred at each concentration of dCF. LARcl7 was selected for dCF resistance in the presence of hypoxanthine, aminopterin, and thymidine (HAT) to select for expression of retrovirus packaging functions. In the cells selected for increased Ada expression, there is a proportional increase in FVIII activity and viral titer (Table 1, bottom) . These results show the titer of virus containing Ada can be amplified by selection for resistance to increasing concentrations of dCF. When amplification of virus titers was attempted in the absence of HAT, no increase in virus titer was observed, although FVIII expression levels increased in the infected cells. This finding is consistent with a loss in the retroviral packaging functions that can occur on prolonged propagation of a retroviral packaging cell line.22
Analysis and amplification of FVIII expression in infected 3T3 cells. 3A8 clones were initially analyzed for their ability to produce FVIII activity. The results (Table 2) show that several 3A8 clones selected for Ada expression also produce FVIII activity. Thus, recombinant retroviruses are capable of transmitting a functional gene encoding human FVIII. Two of three clones (3A8.8~1 and 3A8.8~3) infected with virus from the LARc8 line produced no detectable FVIII activity ( Table 2 ). The infected cells, which do not express FVIII but are resistant to dCF, may result from either infection by a subpopulation of viruses from the packaging line that have deleted the FVIII gene, or from a rearrangement of the viral genome in recipient 3T3 cells on infection.
The 3A8 clones that express FVIII activity were selected for growth in increasing concentrations of dCF. In the 3A8.8~4 cell line, cells resistant to 100 nmol/L dCF produce approximately 20-fold more FVIII activity than do the initial infected cells selected for growth in 10 nmol/L dCF ( Table  2) . Further selection for cells resistant to higher concentrations of dCF failed to produce higher amounts of FVIII. This were infected with 2 mL virus stock and 1 mL medium containing polybrene, and were subcultured into selective medium as described in Materials and
Methods. The total number of drugresistant colonies at each concentration of dCF were counted on single plates (top) or three plates (bottom) 12 to 14 days later. Cells initially selected for resistance to 5 nmol/L dCF were subsequently grown in 10 nmol/L dCF (see Table 2 ). may result from the xyol-A +. dCF selection protocol. in which only limited amplification of Ada genes is obtained due to dclction of adenosine kinase activity:" Greater amplification has been obtained with other cell lines using an and PA317 cells, and derivatives "raining stable copies of RecroLA-SVAda DNA. LAR packaging cell lines were generated by fusion with bacterial protoplasts containing pRetroLA-SVAda. 3A8 infecrants were selected for Ada expression aher infection with retrovirus produced by the LAR packaging lines. Conditions for aeleetion of cells expressing the Ada marker are described in Matsriala and Methods. Total cellular DNA (10 pg) was digested with BsmHI, electrophoresed through a 0.8% agaroae gel. transferred to nitrocellulose. and hybridized to a FVlll probe. pRetroLA-SVAda Southern blot analysis of DNA showed no detectable rearrangement of the expression vector after protoplast fusion into PA31 7 cells. The restriction pattern of integrated plasmid DNA is indistinguishable from the starting plasmid after hybridization to either FVlll (Fig 2A. lanes 3. X. and  12) or Ada probes (data not shown). consistent with hcad-totail integration of a large number of plasmid muliimers on protoplast fusion. DNA from the LARcl7 packaging line was analyzed in more detail due to the unexpectcdl! high gene copy number seen in this and other LAR cell lines. Southern blot analysis of Wirt supernatant DVA versus high molecular weight chromosomal DNA indicated the vector is present predominantly within chromosomal D S A (data not shown). Furthermore. the methylation pattern. as dctermined by Dpnl and Mho1 restriction en7yme sensitivity. (Fig 2R) or Ada probes (data not shown), respectively. In addition, each transfected or infected cell line contains an internal 2.8-kilobase (kb) LA-V l l l BomHl fragment migrating slightly above a doublet of 2.5-kb. The 2.5-kb doublet presumably results from hybriditation of the human FVlll cDNA probe to the mouse FVlll gene. since it is also present in 3T3 and PA3 I7 cells (Fig 2R.  lanes 1 and 2) . Comparison of 3A8.8~4 in 10 nmol/L dCF versus 100 nmol/L dCF (Fig 2R. lanes 6 and 7) demonstrates approximately a IO-fold amplification of the retroviral genome on selection for drug resistance. Interestingly. the LAR packaging lines contain approximately I ,000-fold more copies of the RetroLA-SVAda genome than do the 3A8 infectants. Recause the packaging cell line and the infected cell lines have both bcen selected for resistance to similar concentrations of dCF. expression of the genome via retroviral infection appears much more eficient than by protoplast fusion. The differences in the rcstriction pattern and gene copy number between the LAR packaging lines and the ZAU infectants show that the 3T3 cells were not contaminated by the packaging cell line during the infection process. R S A analysis by Northern blot hybriditation detects two transcripts in LAR clones and 3AX infectants from the pRctro1-A-SVAda vector that arc not observcd in the parental cell lines (Fig 3) . Hybriditation with an FVlll probe shows a single transcript of approximately 8 kb. Hybriditation with a probe to human Ada shows a transcript of 8 kb and a second transcript of approximately 3 kb that is present at several hundred-fold higher levels. These transcripts arc the sizes expected from expression of the intact retroviral vector (Fig I ) . The band migrating at 28s may represent cross-hybriditation of the probe to 28s ribosomal RNA. The source of the mRNA migrating slightly below 28s ribosomal RNA that hybridizes to the Ada probe is unknown. Selection for increasing Ada expression resulted in amplified expression of the FVlll m R N A (Fig 3. lanes 3 and 4.7 and 8) . The greater abundance of Ada mRNA from the internal SV40 promoter may result from higher transcription from this promoter relative to the LTR promoter. and/or from instability of the FVIII/Ada transcript. Previous analyses demonstratcd that FVlll mRNA is produced at much lower quantities than other transcripts cxprcsscd from the same vectors." These analyses. together with Southern blot analyses (Fig 2) . demonstrate that the retroviral genome is largely intact and is cxpresscd in most of the infcctcd 3T3 cells and packaging cell lines.
L A V l l l protein produced by 3AU.8~4 (100 nmol/L dCF) was compared with that produced in CHO cells. in which the L A V l l l gene was introduced by standard transfection procedures. The results (Fig 4) show that both the initial single-chain translation products (lanes 2 and 4) The availability o f a molecular clone for the human F V l l l gene has lead to a tremendous advance in our understanding o f the functional domains of this complex plasma glycoprotein. The availability o f a high titer retrovirus capable o f transferring an F V l l l gene into a variety o f cells will facilitate the studies o f F V l l l synthesis in heterologous cells. Such a virus will also make gene therapy o f hemophilia A a future possibility. The v i r u m described here are not suitable for these purposes. but demonstrate the feasibility o f retrovital gene transfer o f a human F V l l l gene and a gene encoding a dominant selectable amplifiable marker. Recently. Palmer et al?' reported that the human factor I X clotting factor can be transferred into rodent and human fibroblasts using eficient retroviral vectors. Improvements in the design o f FVIII-containing retorviral vectors will increase their utility in gene transfer experiments.
